
Elcelyx Therapeutics
Total Raised
$90.34MInvestors Count
7Deal Terms
6Funding, Valuation & Revenue
9 Fundings
Elcelyx Therapeutics has raised $90.34M over 9 rounds.
Elcelyx Therapeutics's latest funding round was a Debt for $0.48M on November 7, 2018.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/7/2018 | Debt | $0.48M | Undisclosed Investors | 1 | ||
10/1/2015 | Series E | |||||
2/19/2015 | Series D - II | |||||
2/21/2014 | Series D | |||||
2/14/2013 | Series C |
Date | 11/7/2018 | 10/1/2015 | 2/19/2015 | 2/21/2014 | 2/14/2013 |
|---|---|---|---|---|---|
Round | Debt | Series E | Series D - II | Series D | Series C |
Amount | $0.48M | ||||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Elcelyx Therapeutics Deal Terms
6 Deal Terms
Elcelyx Therapeutics's deal structure is available for 6 funding rounds, including their Series E from October 01, 2015.
Round | Series E | Series D - II | Series C | Series B - II | Series B |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series E | |||||||||||||||
Series D - II | |||||||||||||||
Series C | |||||||||||||||
Series B - II | |||||||||||||||
Series B |
Elcelyx Therapeutics Investors
7 Investors
Elcelyx Therapeutics has 7 investors. Kleiner Perkins invested in Elcelyx Therapeutics's Series E funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/16/2011 | 10/1/2015 | 6 Series B, Series B - II (2012), Series C (2013), Series D (2014), Series D - II (2015), Series E (2015) | Venture Capital | California | ||
Venture Capital | California | |||||
Venture Capital | California | |||||
Asset/Investment Management | Colorado | |||||
Private Equity | China |
First funding | 5/16/2011 | ||||
|---|---|---|---|---|---|
Last Funding | 10/1/2015 | ||||
Investor | |||||
Rounds | 6 Series B, Series B - II (2012), Series C (2013), Series D (2014), Series D - II (2015), Series E (2015) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Asset/Investment Management | Private Equity |
Location | California | California | California | Colorado | China |
Compare Elcelyx Therapeutics to Competitors

Biolog focuses on microbial phenotypic characterization and polyphasic identification within the biotechnology sector. The company provides methods for the characterization of microbial and mammalian cells and the identification of various bacteria, yeast, and fungi species. It was founded in 1984 and is based in Hayward, California.
MI Research, Inc. specializes in Biotech instrumentation with excellent visualization capabilities in the area of protein crystal growth and blood viscosity measurements. MI aims to offer fluorescence base protein crystallization prescreening service and biotech instruments like blood viscometers. MI's expertise is in optics and biochemistry.

BioSkills is a service company founded to provide its customers with basic and advanced skills in life science and biotech area. BioSkills achieves its primary objectives by developing original formation initiatives in order to spread relevant knowledge base.
Martin-Protean focuses on determining the three-dimensional structure of proteins and analyzing protein interactions in the biotechnology and pharmaceutical sectors. The company provides services such as discovering protein-protein interfaces, drug-binding sites, and quantifying hormones like oxytocin in biological samples using mass spectrometry. It is based in Chicago, Illinois.
greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins

Oligomerix operates as a clinical-stage biotechnology company involved in the development of therapeutics for neurodegenerative diseases. The company provides oral, small-molecule drugs that inhibit tau protein self-association, addressing conditions such as Alzheimer's disease and rare tauopathies. Oligomerix targets the healthcare sector focusing on neurodegenerative disorders. It was founded in 2006 and is based in the Bronx, New York.
Loading...

